GSK's sales catch a winter cold

Thursday 28 April 2011 00:00 BST

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

GlaxoSmithKline's sales dropped in the first quarter as revenue from flu products fell away sharply compared with last year's pandemic-linked surge.

Britain's biggest drug-maker admitted the first three months of 2011 were tough but said underlying growth was improving as its treatments adjust to pricing pressure and competition from generics.

Quarterly sales fell 10 per cent to £6.59bn but earnings per share rose 9 per cent as gains on sales of businesses cushioned profits from declining revenues.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

GSK's sales catch a winter cold

Join our commenting forum

Thank you for registering